As of April 26, 2025, LakeShore Biopharma (LSB) has a market cap of $25.377 million USD. According to our data, LakeShore Biopharma is ranked No.8465 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 26, 2025 | $25.38 M |
-61.56%
|
Dec 31, 2024 | $66.02 M |
-32.29%
|
Dec 29, 2023 | $97.50 M |
-94.90%
|
Dec 30, 2022 | $1.91 B |
3.14%
|
Dec 31, 2021 | $1.85 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Gilead Sciences
GILD
|
$132.33 B |
3.883 B
|
![]() USA
|
![]() Amgen
AMGN
|
$150.87 B |
0.008 M
|
![]() USA
|
![]() Biogen
BIIB
|
$17.49 B |
98.043 M
|
![]() USA
|
![]() Regeneron Pharmaceuticals
REGN
|
$65.57 B |
0.780 B
|
![]() USA
|
![]() Vertex Pharmaceuticals
VRTX
|
$126.96 B |
0.004 M
|
![]() USA
|
![]() Moderna
MRNA
|
$10.59 B |
65.708 M
|
![]() USA
|
![]() BioMarin Pharmaceutical
BMRN
|
$12.14 B |
-0.000 M
|
![]() USA
|
![]() Alnylam Pharmaceuticals
ALNY
|
$32.56 B |
-0.000 M
|
![]() USA
|
![]() Sarepta Therapeutics
SRPT
|
$5.99 B |
0.128 B
|
![]() USA
|
![]() Ionis Pharmaceuticals
IONS
|
$4.72 B |
0.000 M
|
![]() USA
|
![]() Exelixis
EXEL
|
$10.32 B |
0.000 M
|
![]() USA
|
![]() Blueprint Medicines
BPMC
|
$5.60 B |
0.000 M
|
![]() USA
|
![]() Sage Therapeutics
SAGE
|
$0.48 B |
0.000 M
|
![]() USA
|
Market Cap | = | LSB Stock Price | * | LSB Shares Outstanding |
= | $1.22 | * | 19.08 M | |
= | $25.38 M |